Pharmaron Inc. provides research and development services, including laboratory chemistry, biosciences, and clinical development services.

Pharmaron Inc.

Biotechnology Research

Pharmaron Biologics (UK) Ltd

Pharmaceutical Manufacturing

Pharmaron US Lab Services

Pharmaron Beijing

Pharmaron, Clinical Development

Pharmaron, Radiolabelled Sciences Division

Pharmaron | 38,324 followers on LinkedIn. Premier life science service provider | Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 20,000 employees and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&amp;D solutions to its partners in North America, Europe, Japan and China.

Amarjit Girn

Senior Radiochemist at Pharmaron Radiolabelled Sciences

John Townsley

Fabio Spreafico

VP, Business Development (Safety Assessment)

Allison Perkins

Pharmaron

Join us on 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟱𝘁𝗵 𝗮𝘁 𝟴𝗮𝗺 𝗣𝗧 / 𝟭𝟭𝗮𝗺 𝗘𝗧 / 𝟰𝗽𝗺 𝗚𝗠𝗧 for an in-depth exploration of 𝗺𝗮𝗰𝗿𝗼𝗰𝘆𝗰𝗹𝗲𝘀 in drug design and discovery! In this webinar, Mike Waring , Professor and Head of Medicinal Chemistry at Newcastle University, and Sebastien Campos , Senior Director of Medicinal Chemistry at Pharmaron, will explore how macrocycles are transforming the field. Discover key principles for rational macrocycle design and learn about the unique benefits and challenges of this compound class. Don’t miss the opportunity to gain insights from leading experts in the field—reserve your spot today! 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/dDDxTFic #Pharmaron #Webinar #Macrocycles #DrugDesign #DrugDiscovery

Today is World Diabetes Day—a reminder of the urgent need for continued research to address the rising global impact of diabetes. With over 537 million adults affected worldwide, diabetes requires innovative approaches to improve both prevention and treatment. Pharmaron is committed to supporting research that advances understanding and drives new possibilities in diabetes care. We collaborate with scientists and pharmaceutical innovators through strategic partnerships to accelerate diabetes research and foster solutions that can make a lasting difference for patients. Learn more about our commitment to health innovation: https://lnkd.in/dvCVPZ9V #WorldDiabetesDay #DiabetesResearch #Pharmaron #HealthInnovation #LifeSciences

The next CGT webinar is fast approaching! Join us in less than a week to learn more about Pharmaron’s AAV Production Platform. We’ll explore how our advanced strategies can facilitate the AAV product development process leading to BLA/MAA submission. Our agenda features: > Overview of AAV as a therapeutic agent > Key considerations for optimizing the platform > Effective strategies to overcome production challenges Date: November 19, 2024 Time: 8am PST / 11am EST / 4pm GMT Register: https://lnkd.in/dyiasHNG #BiologicsDevelopment #Pharmaron #Webinar #LifeSciences

On World Kindness Day, we celebrate kindness's profound impact across all aspects of life—including science and healthcare. Acts of kindness fuel collaboration, inspire trust and ultimately drive the innovations that improve patient care worldwide. At Pharmaron, kindness is at the heart of our partnerships. By working with integrity and empathy, we aim to create a supportive environment where scientists, researchers, and innovators can thrive together toward better health solutions for all. Let’s make kindness our guiding principle every day. Learn more about our commitment to collaborative success: https://lnkd.in/dvCVPZ9V #WorldKindnessDay #KindnessInScience #Pharmaron #LifeSciences #HealthInnovation

Check out this webinar, which is happening tomorrow in the Bioanalysis Zone. Pharmaron is proud to support this webinar on "The origin-adjusted approach for biomarker quantification by LC–MS". Learn how this approach can enhance your biomarker workflows. https://lnkd.in/d28Jpfrq

Discover when infusion is the best option for drug dosing in animal studies. To learn more, download our flyer here: https://lnkd.in/dGZD6FvN #Pharmacokinetics #DrugDelivery #DrugDiscovery #DrugDevelopment #Pharmaron

Join us at the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗕𝗶𝗼𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗙𝗼𝗿𝘂𝗺 on 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬-𝟮𝟮, 𝟮𝟬𝟮𝟰, where our Analytical Services Manager, Neil Adcock , will present a poster on "Development of an LC/MS/MS method for determination of 4-beta-hydroxycholesterol in Human Plasma". If you are not able to attend, schedule a time to discuss your upcoming projects with our local team by clicking here: https://lnkd.in/dXXaGRif #Pharmaron #EBF #Poster #Bioanalysis

Pharmaron is excited to be a Gold Sponsor at 𝐁𝐎𝐒 𝐌𝐚𝐧𝐜𝐡𝐞𝐬𝐭𝐞𝐫 𝐨𝐧 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟔-𝟐𝟕! Join us at 𝐁𝐨𝐨𝐭𝐡 #𝟏𝟏 to meet our team and discover how our fully integrated drug substance and drug product solutions position Pharmaron as a 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐠𝐥𝐨𝐛𝐚𝐥 𝐂𝐃𝐌𝐎 𝐩𝐚𝐫𝐭𝐧𝐞𝐫. Don’t miss the chance to connect - request a meeting with us today: https://lnkd.in/d2U6tbAE #Pharmaron #BOSManchester #CDMO #LifeSciences #DrugDevelopment #Innovation Javier Ruiz Sanz Natalie Windle Paul Quigley Nicolas Duchemin Kassim Kolia

Join us at the 𝗜𝗜𝗦 𝗨𝗞 𝟯𝟬𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 on 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟱, 𝟮𝟬𝟮𝟰! Our Tritium Deputy Team Leader, Siôn Edwards , will be presenting on “Tritium Labelling of Oligonucleotides” at 9:55 am at The Møller Institute, Cambridge. Don’t miss this opportunity to gain insights into cutting-edge advancements in tritium labelling! #Pharmaron #IIS #Tritium #Oligonucleotides #LifeSciences

November is Alzheimer’s Disease Awareness Month—a time to acknowledge the profound impact this disease has on over 50 million individuals and their families globally. At Pharmaron, we are committed to advancing research that addresses the complexities of Alzheimer’s, from preclinical development to clinical trials, and helping pave the way for more effective treatment options. By partnering with pharmaceutical innovators, we support and accelerate crucial research efforts that could one day transform the future of Alzheimer’s care, offering hope to patients, families, and caregivers worldwide. Learn more about our work in neuroscience research: https://lnkd.in/dvCVPZ9V #AlzheimersAwarenessMonth #Pharmaron #Neuroscience #AlzheimersResearch #HealthInnovation #LifeSciences

IPv6

Ops One

Boliang Lou

Chief Scientific Officer

Hua Yang

Chief Business Officer

Katherine Lee

Paralegal/Owner

Lisa Thompson

Vice President, Business Development, Clinical Development

Andrew Slack

Senior Vice President, Strategy

Ashok Tehim

Vice President, Business Development, Pharmacology

Cheng Jin

Senior Vice President, Business and Corporate Development

Connie Sun

Vice President, Drug R&D Services

Erich Grimm

Marie Croft

Director of Scientific Operations

Sid Bhoopathy

SVP of US Head of Laboratory Services and CGT

Founder, Chairman, CEO

Christopher Sadler

Director, Process Sciences

Scientific Director, Radiolabeled Sciences

Louise Almond

Associate Director Technical Specislist, Process Sciences

Andy Slack

VP, Business Development, Radiolabeled Sciences & Metabolism

Imago is a clinical stage biopharmaceutical company that develops drugs for the management of proliferative diseases of the bone marrow.

China Companies With More Than 10 Employees (Top 10K)

Beijing Public Companies With More Than $50M in Revenue

China Companies With More Than 100 Employees (Top 10K)

Beijing Companies

Pharmaron provides research, development, and manufacturing services throughout the drug discovery, preclinical, and clinical development processes across therapeutic modalities, including small molecules, biologics, and CGT products. Their services include laboratory chemistry, biosciences, chemistry, manufacturing, safety assessment, clinical development, and drug discovery services.

Post-IPO Equity - Pharmaron

CITIC M&A Fund

Legend Capital

Venture Round - Pharmaron

GL Capital

Series C - Pharmaron

Series A - Pharmaron

Beijing

China

Asia

Pharmaron's HK stock jumps most in 4-1/2 months on solid earnings estimates

Pharmaceutical manufacturer Pharmaron's Cramlington base set for investment despite losses

Pharmaron Beijing Full Year 2023 Earnings: In Line With Expectations

Contract Research Organization Services Market / CRO Services Market Worth $129.8 Billion | MarketsandMarkets™

CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA

Pharmaron finalizes Rhodes site acquisition in Coventry

Pharmaron Acquires Commercial API Manufacturing Facility in the United States

Pharmaron Acquires Commercial API Manufacturing Facility in the United Kingdom from Recipharm

Pharmaron Announces Promotion of Ms. Katherine Lee to Chief Business Officer

Pharmaron offers research, development, and manufacturing services across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and CGT products.

Pharmaron provides laboratory chemistry services including analytical, purification, synthetic, radiolabelling, medicinal, computational, and DNA-encoded library chemistries to support drug discovery and development.

Pharmaron offers services in radiosynthesis, including the synthesis, purification, and analysis of radiolabelled compounds for clinical and preclinical studies.

Pharmaron conducts studies to evaluate metabolic pathways and compound disposition in soil, sediment, and water, including environmental risk assessments for pharmaceuticals and veterinary products.

Pharmaron provides DMPK services for small molecule drug discovery and development, including ADME, radiolabelled metabolism, toxicity, and pharmacokinetics studies.

Pharmaron conducts dermal penetration studies to assess topical risk exposure and support regulatory approval for agrochemicals, cosmetics, pharmaceuticals, and chemicals.

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:44 PM	c2d8c4d8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:44 PM	4553fdc3
crunchbase trigger	general	Nov 17, 2024 8:44 PM	eceb15f4
crunchbase profile	general	Nov 17, 2024 9:04 PM	af98f799
li profile	general	Nov 17, 2024 8:44 PM	62c15c0f
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	6fbbea69
peers	general	Nov 17, 2024 8:44 PM	abacbd07
news basic	general	Nov 17, 2024 8:44 PM	a08f9a46
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

PHAR

CN:PHARMARON

Pharmaron Inc.